<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02684032</url>
  </required_header>
  <id_info>
    <org_study_id>B2151009</org_study_id>
    <nct_id>NCT02684032</nct_id>
  </id_info>
  <brief_title>A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer</brief_title>
  <official_title>PHASE 1B STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND CLINICAL ACTIVITY OF GEDATOLISIB IN COMBINATION WITH PALBOCICLIB AND EITHER LETROZOLE OR FULVESTRANT IN WOMEN WITH METASTATIC OR LOCALLY ADVANCED/RECURRENT BREAST CANCER (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celcuity, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celcuity, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, open label, Phase 1b study in patients with mBC. This study will have&#xD;
      a dose escalation to identify the maximum tolerated dose (MTD) of the combination of&#xD;
      gedatolisib plus palbociclib/fulvestrant and gedatolisib plus palbociclib/letrozole and&#xD;
      expansion to estimate the objective response rate (OR) of the combination of gedatolisib plus&#xD;
      palbociclib/letrozole or palbociclib/fulvestrant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, open label, continuous Phase 1b study in patients with MBC. This study&#xD;
      will have a dose escalation and expansion. The dose escalation will identify the maximum&#xD;
      tolerated dose (MTD) of the combination of gedatolisib plus palbociclib/fulvestrant and&#xD;
      gedatolisib plus palbociclib/letrozole. The expansion will estimate the objective response&#xD;
      rate (OR) of the combination of gedatolisib plus palbociclib/letrozole and the combination of&#xD;
      gedatolisib plus palbociclib/fulvestrant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 14, 2016</start_date>
  <completion_date type="Anticipated">June 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 11, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>up to 28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate observed in patients in the dose expansion portion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients for each response category, objective response rate (number of patients with a complete response (CR)) relative to the number of response evaluable patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate observed in patients in the dose expansion portion</measure>
    <time_frame>16 weeks</time_frame>
    <description>Number of patients for each response category, objective response rate (number of patients with a partial response (PR)) relative to the number of response evaluable patients)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response observed in patients in the dose escalation portion</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QTc interval (corrected QT interval)</measure>
    <time_frame>Screening up to 6 months</time_frame>
    <description>The QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the heart's electrical cycle.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration</measure>
    <time_frame>Day 1: 0, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 24, 72 and 168 hours. Cycle 2 Day 1: 0, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 24, 72 and 168 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>16 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">141</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Letrozole Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Letrozole combination cohort in dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fulvestrant combination cohort in dose escalation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + letrozole in dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + fulvestrant in dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib + palbociclib + fulvestrant in dose expansion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gedatolisib (3:1) + palbociclib + fulvestrant in dose expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gedatolisib</intervention_name>
    <description>Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_label>Letrozole Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palbociclib</intervention_name>
    <description>Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
    <arm_group_label>Letrozole Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Letrozole at 2.5 mg daily</description>
    <arm_group_label>ARM A</arm_group_label>
    <arm_group_label>Letrozole Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <description>Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.</description>
    <arm_group_label>ARM B</arm_group_label>
    <arm_group_label>ARM C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Fulvestrant cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women 18 years of age or older, who are either: Postmenopausal or Pre/perimenopausal&#xD;
             women with medically-induced menopause by treatment with agents to induce chemical&#xD;
             menopause.&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of breast cancer with evidence of&#xD;
             metastasis.&#xD;
&#xD;
          -  Documentation of estrogen receptor positive ((ER+), human epidermal growth factor&#xD;
             receptor 2 (HER2 negative (HER2-)) tumor.&#xD;
&#xD;
          -  Dose Escalation Portion: Patients must satisfy one of the following criteria:&#xD;
&#xD;
               -  Letrozole combination cohort (L): metastatic breast cancer (MBC) with progression&#xD;
                  who are candidates for a letrozole-containing regimen, with palbociclib.&#xD;
&#xD;
               -  Fulvestrant combination cohort (F): MBC with progression who are candidates for a&#xD;
                  fulvestrant containing regimen, with palbociclib.&#xD;
&#xD;
          -  Dose Expansion Portion: Patients must satisfy one of the following criteria:&#xD;
&#xD;
               -  Arm A: MBC with progression and no prior endocrine based systemic therapy in the&#xD;
                  metastatic setting;&#xD;
&#xD;
               -  Arm B: MBC with progression during or following one prior endocrine based&#xD;
                  systemic therapy in the metastatic setting, with no prior therapy with any&#xD;
                  cyclin-dependent kinase (CDK) inhibitor;&#xD;
&#xD;
               -  Arm C/Arm D: MBC with progression during or following one or two prior endocrine&#xD;
                  based systemic therapies in the metastatic setting, and following prior therapy&#xD;
                  with a CDK inhibitor.&#xD;
&#xD;
          -  Measurable disease as defined by Response Evaluation Criteria In Solid Tumors (RECIST)&#xD;
             version 1.1.&#xD;
&#xD;
          -  Bone only patients during dose escalation portion.&#xD;
&#xD;
          -  Availability of archival tumor biopsy sample or willing to provide fresh biopsy if not&#xD;
             available.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group [ECOG] performance must be 0 or 1.&#xD;
&#xD;
          -  Adequate bone marrow, renal and liver function.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with a mechanistic target of rapamycin (mTOR) inhibitor or&#xD;
             phosphoinositide 3-kinase (PI3K) inhibitor.&#xD;
&#xD;
          -  More than 1 line of prior chemotherapy in the treatment of metastatic or locally&#xD;
             advanced/recurrent disease.&#xD;
&#xD;
          -  Bone only patients during expansion/efficacy portion.&#xD;
&#xD;
          -  Patients with advanced/metastatic disease who have symptomatic visceral spread, and&#xD;
             who have life threatening complications needing immediate therapy, such as massive&#xD;
             uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and&#xD;
             over 50% liver replacement with tumor.&#xD;
&#xD;
          -  Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases.&#xD;
&#xD;
          -  Active bacterial, fungal or viral infection.&#xD;
&#xD;
          -  Uncontrolled or significant cardiovascular disease.&#xD;
&#xD;
          -  Radiation therapy within 4 weeks of investigational product.&#xD;
&#xD;
          -  Cytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for&#xD;
             mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3&#xD;
             4 week schedule or 2 weeks of investigational product if immediate prior regimen&#xD;
             consisted of weekly therapy.&#xD;
&#xD;
          -  Any other anti cancer agents (eg, hormonal, biological, investigational) within 5&#xD;
             times the half life prior to investigational product.&#xD;
&#xD;
          -  Impairment of gastro intestinal (GI) function or GI disease.&#xD;
&#xD;
          -  Pregnant female patients; breastfeeding female patients; and female patients of&#xD;
             childbearing potential who are unwilling or unable to use 2 highly effective methods&#xD;
             of contraception as outlined in this protocol for the duration of the study and for 90&#xD;
             days.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Igor Gorbatchevsky, MD</last_name>
    <role>Study Director</role>
    <affiliation>Celcuity, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Corona</city>
        <state>California</state>
        <zip>92879</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC - Norris Healthcare Center (HC3)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keck Hospital of USC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LAC+USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center / Investigational Drug Services</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group Inc. at Compassionate Cancer Care Medical Group, Inc.</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF - Helen Diller Family Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Inpatient Pavilion (AiP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital - Clinical Trials Office (CTO)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital- Anschutz Cancer Pavilion (ACP)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center Richard M Schulze Family Foundation Outpatient Center at McKinley Campus</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital Midtown</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Cancer Hospital Infusion Pharmacy</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals, The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stefanie Spielman Comprehensive Breast Cancer</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University - Clinical and Regulatory</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Breast Center at One Hundred Oaks</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry-Joyce Cancer Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.T. MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance (SCCA) Investigational Drug Services</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B2151009</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 10, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PI3K (phosphoinositide 3-kinase)</keyword>
  <keyword>mTOR (mechanistic target of rapamycin)</keyword>
  <keyword>PI3K/mTOR</keyword>
  <keyword>metastatic breast cancer (MBC)</keyword>
  <keyword>ER+ (estrogen receptor positive)</keyword>
  <keyword>HER2- (human epidermal growth factor receptor 2 negative)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Palbociclib</mesh_term>
    <mesh_term>Gedatolisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Celcuity will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

